Loading organizations...
§ Private Profile · Nanjing, Jiangsu, China
Clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies for solid tumors and hematological malignancies.
Bioheng is a clinical-stage biopharmaceutical company based in Nanjing, China, that develops allogeneic CAR-T cell therapies and cellular immunotherapies for advanced cancer treatment. The biotechnology firm engineers "off-the-shelf" treatments targeting both hematological malignancies and solid tumors, including specific oncology indications like gastric cancer. The enterprise operates a 7,500 square meter GMP manufacturing plant and has applied for 52 core patents to support its proprietary cell and gene therapy pipeline. Bioheng has accumulated $100 million in total venture financing, which includes an $80 million Series B funding round co-led by GL Ventures, Decheng Capital, Octagon Capital, and BlueRun Ventures China. Its pipeline includes autologous and allogeneic products such as CTB001 and CTA101, which have received Orphan Drug Designation from the United States Food and Drug Administration. The organization was founded in 2017 by researchers Lu Han and Xiaohong He.
Bioheng has raised $80.0M across 1 funding round.
Bioheng has raised $80.0M in total across 1 funding round.
Bioheng has raised $80.0M in total across 1 funding round.
Bioheng's investors include Decheng Capital, Octagon Capital, BlueRun Ventures China, Shenzhen Capital Group.
Bioheng has raised $80.0M across 1 funding round. Most recently, it raised $80.0M Series B in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 5, 2021 | $80M Series B | Decheng Capital, Octagon Capital | BlueRun Ventures China, Shenzhen Capital Group | Announced |